Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 11/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.33 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.33 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | MME | P08473 | 1/20 | 0.31 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
| ▸ | CPA1 | P15085 | 1/20 | 0.31 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9092111 | 0.84 | SLC6A3 (0.35) | OPRD1SLC6A2SLC6A4MMEACE | |
| SCHEMBL2597712 | 0.77 | DPP4 (0.32) | OPRD1 | |
| SCHEMBL9621736 | 0.71 | OPRD1 (0.40) | OPRD1SIGMAR1CHRM5CHRM3OPRM1 | |
| SCHEMBL928299 | 0.71 | SLC6A2 (0.33) | OPRD1SIGMAR1CHRM5CHRM3SLC6A2 | |
| SCHEMBL1494478 | 0.71 | SIGMAR1 (0.43) | OPRD1SIGMAR1CHRM5CHRM3OPRM1 | |
| SCHEMBL7590414 | 0.71 | SIGMAR1 (0.43) | OPRD1SIGMAR1CHRM5CHRM3OPRM1 | |
| Propionic Acid SCHEMBL28240809 | 0.71 | SIGMAR1 (0.41) | OPRD1SIGMAR1CHRM5CHRM3OPRM1 | |
| Hydrochloric Acid SCHEMBL28404227 | 0.69 | SIGMAR1 (0.42) | OPRD1SIGMAR1CHRM5CHRM3OPRM1 | |
| SCHEMBL29926322 | 0.69 | SIGMAR1 (0.42) | OPRD1SIGMAR1CHRM5CHRM3OPRM1 | |
| SCHEMBL3928119 | 0.69 | SIGMAR1 (0.33) | OPRD1SIGMAR1CHRM5CHRM3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3047274-A2 | PSA ENZYMATIC ACTIVITY: A NEW BIOMARKER FOR ASSESSING PROSTATE CANCER AGGRESSIVENESS | Ohmx Corporation (US) | 2016-07-27 | — | — | EP | disclosed |
| WO-2015042493-A2 | PSA ENZYMATIC ACTIVITY: A NEW BIOMARKER FOR ASSESSING PROSTATE CANCER AGGRESSIVENESS | OHMX CORPORATION (US) | 2015-03-26 | — | — | WO | disclosed |
| US-20140322740-A1 | PSA PEPTIDASE ACTIVITY (PPA) AS A PROSTATE CANCER BIOMARKER | NORTHWESTERN UNIVERSITY, AN ILLINOIS NOT FOR PROFIT CORPORATION (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140134658-A1 | PSA ENZYMATIC ACTIVITY: A NEW BIOMARKER FOR ASSESSING PROSTATE CANCER AGGRESSIVENESS | NOTRHWESTERN UNIVERSITY, AN ILLINOIS NOT FOR PROFIT CORPORATION (US) | 2014-05-15 | — | — | US | disclosed |
| EP-2571997-A2 | ENZYMATIC ACTIVITY OF PSA AS DIAGNOSTIC MARKER FOR PROSTATE CANCER | Ohmx Corporation (US) | 2013-03-27 | — | — | EP | disclosed |
| US-20120034638-A1 | Electrochemical assay for the detection of enzymatically active PSA | NORTHWESTERN UNIVERSITY, AN ILLINOIS NOT FOR PROFIT CORPORATION | 2012-02-09 | — | — | US | disclosed |
| WO-2011146143-A2 | DETECTION OF CANCER BY ASSAYING PSA ENZYMATIC ACTIVITY | OHMX CORPORATION (US) | 2011-11-24 | — | — | WO | disclosed |
| US-6844318-B2 | Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use | BRISTOL MYERS SQUIBB PHARMA COMPANY (US) | 2005-01-18 | — | — | US | disclosed |
| EP-1263473-A2 | PEPTIDASE-CLEAVABLE, TARGETED ANTINEOPLASTIC DRUGS AND THEIR THERAPEUTIC USE | Bristol-Myers Squibb Pharma Company (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20020103133-A1 | Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-01 | — | — | US | disclosed |
| WO-2001068145-A2 | PEPTIDASE-CLEAVABLE, TARGETED ANTINEOPLASTIC DRUGS AND THEIR THERAPEUTIC USE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103133-A1 | Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use | DNPEP, TMPRSS15, ENPEP | OPRD1 4410/4885SIGMAR1 4271/4885CHRM5 4811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.